duloxetine hydrochloride has been researched along with Depressive Disorder, Major in 372 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 134 (36.02) | 29.6817 |
| 2010's | 207 (55.65) | 24.3611 |
| 2020's | 31 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barzi, M; Bissig, KD; Chavan, H; Chen, S; Guner, JZ; Guo, L; Hakenjos, JM; Jung, SY; Krishnamurthy, P; Li, F; MacKenzie, KR; Matzuk, MM; Nyshadham, P; Palmer, S; Qin, X; Wang, J | 1 |
| Hein, M; Mungo, A | 1 |
| Alarabi, AB; Alshbool, FZ; Badejo, P; Boakye, ET; El-Halawany, MS; Garcia, SE; Khasawneh, FT; Kingbong, HT; Lozano, PA; Naddour, E; Villalobos-García, D | 1 |
| Athreya, AP; Bobo, WV; Croarkin, PE; Emslie, GJ; Kennard, BD; Leffler, JM; Mayes, T; McKean, AJ; Rackley, SJ; Romanowicz, M; Shekunov, J; Trivedi, M; Vande Voort, JL; Wang, L; Weinshilboum, RM | 1 |
| Ishida, M; Katagiri, H; Matsumoto, H; Nishiyori, A; Ochiai, T; Saito, T | 1 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Ali, AA; El-Ela, FIA; Khallaf, RA; Rabea, YK; Salem, HF | 1 |
| Fürst, S; Langner, C; Varelas, AI | 1 |
| McIntire, GL; Mulder, HA; Poklis, JL; Wallace, FN | 1 |
| Amano, T; Nakatani, Y; Noguchi, R; Ogino, K; Yaguchi, M; Yamamoto, N | 1 |
| Chen, YA; Dong, J; Li, R; Li, T; Li, Z; Liu, J; Wang, Q; Wang, Y; Xue, R; Zhang, T; Zhang, Y; Zhuang, X | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Barzi, M; Bissig, KD; Boyd, SR; Hakenjos, JM; Li, F; MacKenzie, KR; Qin, X; Xie, C; Young, DW | 1 |
| Cha, J; Choi, KS; Craighead, WE; Dunlop, BW; Mayberg, HS; Nemeroff, CB; Rajendra, JK | 1 |
| Chen, C; Fu, B; Guo, H; He, H; He, R; He, S; Hu, Z; Huang, G; Li, H; Li, J; Li, K; Li, L; Li, S; Li, Y; Lu, Z; Lyu, N; Pan, X; Pan, Z; Tan, Y; Wang, G; Wang, Q; Wang, W; Wang, X; Wang, Z; Wei, B; Xu, X; Yang, C; Zhang, X; Zhao, J; Zhao, Q; Zou, S | 1 |
| Ikenouchi, A; Okamoto, N; Yoshimura, R | 1 |
| Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
| Kaibara, A; Kubota, R; Shibata, RY; Uenaka, K; Wajima, T | 1 |
| Cha, J; Choi, KS; Craighead, WE; Dunlop, BW; Mayberg, HS; Nemeroff, CB | 1 |
| Hadryś, T; Machowska, M; Maciaszek, J; Misiak, B; Pawłowski, T; Wiela-Hojeńska, A | 1 |
| Bi, Y; Chen, S; Lian, Z; Xie, G; Yao, G; Yuan, G; Zhou, W; Zhou, Z | 1 |
| Sourdeau, A; Zdanowicz, N | 1 |
| Abe, T; Furukawa, TA; Iwanami, A; Mimura, M; Nakagawa, A; Nakagome, K; Yokoi, Y; Yoshimura, N | 1 |
| Chirila, M; Duna, SN; Ghita, A; Iordachescu, A; Rizea-Savu, S | 1 |
| Holper, L | 1 |
| Furukawa, TA; Imai, H; Noma, H | 1 |
| Bayraktaroglu, Z; Cankaya, S; Ergun, T; Hanoglu, L; Lakadamyali, H; Oktem, EO; Ozsimsek, A; Saatçi, Ö; Uykur, AB; Velioglu, HA; Yıldız, S; Yulug, B | 1 |
| Chen, Y; Hellerstein, DJ; Liu, Z; McGrath, PJ; Peterson, BS; Stewart, JW; Wang, Z; Yang, J | 1 |
| Abe, T; Furukawa, TA; Iwanami, A; Mimura, M; Nakagawa, A; Nakagome, K; Nishioka, G; Tani, M; Watanabe, K; Yokoi, Y; Yoshimura, N | 1 |
| Castellanos, FX; Li, JT; Li, K; Li, L; Si, TM; Su, YA; Wu, YK; Yan, CG | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Barbateskovic, M; Gluud, C; Jakobsen, JC; Juul, S; Katakam, KK; Munkholm, K; Siddiqui, F | 1 |
| Choi, KS; Craighead, WE; Dunlop, BW; Kelley, ME; Kinkead, B; Mayberg, HS; McGrath, CL; Nemeroff, CB; Rajendra, JK | 1 |
| Aponte-Rivera, V; Craighead, WE; Dunlop, BW; Kelley, ME; Kinkead, B; Mayberg, HS; Mletzko-Crowe, T; Nemeroff, CB; Ritchie, JC | 1 |
| Berlim, M; Chachamovich, E; Fiori, LM; Foster, J; Jollant, F; Kennedy, SH; Lopez, JP; Richard-Devantoy, S; Rotzinger, S; Turecki, G | 1 |
| Aitchison, KJ; Blier, P; Cates, HM; Cruceanu, C; Evans, KR; Farzan, F; Feilotter, H; Fiori, LM; Foster, J; Frey, BN; Gerald, C; Giacobbe, P; Han, MH; Heller, EA; Kennedy, SH; Ku, SM; Labonte, B; Lam, RW; Leri, F; Lewis, CM; Lin, R; Lopez, JP; MacQueen, GM; Mechawar, N; Milev, R; Müller, DJ; Nestler, EJ; Parikh, SV; Rotzinger, S; Soares, CN; Strother, SC; Turecki, G; Tyryshkin, K; Uher, R; Vialou, V; Wittenberg, GM | 1 |
| Chen, S; Jiang, H; Jiang, W; Liang, J; Lu, N; Yin, Y; Yuan, Y; Yue, Y; Zhang, Y | 1 |
| Barbui, C; Breilmann, J; Guaiana, G; Koesters, M; Ostuzzi, G | 1 |
| Fonseka, TM; Foster, JA; Freeman, N; Kennedy, JL; Kennedy, SH; Maciukiewicz, M; Marshe, VS; Müller, DJ; Rotzinger, S; Tiwari, AK | 2 |
| Dubois, T; Jacques, D; Lepiece, B; Reynaert, C; Zdanowicz, N | 1 |
| Christensen, MC; Munro, V | 1 |
| Cole, SP; Craighead, WE; Dunlop, BW; Mayberg, HS; Nemeroff, CB | 1 |
| Foster, JA; Geraci, J; Hauschild, AC; Kennedy, JL; Kennedy, SH; Maciukiewicz, M; Marshe, VS; Müller, DJ; Rotzinger, S | 1 |
| Gündüz, C; Kılınçel, O; Parmak Yener, N; Uçan Gündüz, G | 1 |
| Memon, NA; Shanker, R; Siddiqui, SH | 1 |
| Becker, T; Breilmann, J; Furukawa, TA; Koesters, M | 1 |
| Christensen, MC; Loft, H; McIntyre, RS | 1 |
| Chang, CL; Kao, WT; Lung, FW | 1 |
| Ajilore, O; Bessette, KL; Crane, NA; DelDonno, SR; Hsu, DT; Klumpp, H; Langenecker, SA; Leow, A; Mickey, BJ; Peters, AT; Phan, KL; Ransom, MT; Shankman, SA; Stange, JP; Walker, SJ; Zubieta, JK | 1 |
| Binder, EB; Carrillo-Roa, T; Craighead, WE; Dunlop, BW; Kelley, ME; Kutner, MH; Lori, A; Mayberg, HS; Nemeroff, CB; Rivera, VA | 1 |
| Enomoto, T; Hasegawa, R; Hori, N; Inada, E; Isek, M; Katsuta, Y; Koh, K; Saito, R; Sugasawa, Y; Sugita, M; Takahashi, Y; Yamaguchi, K | 1 |
| Andreazza, AC; Dharsee, M; Elmi, N; Evans, KR; Feilotter, H; Good, J; Javadi, M; Kim, HK; McCormack, S; Tyryshkin, K; Vaccarino, AL; Zhang, X | 1 |
| Conca, A; De Donatis, D; Florio, V; Mercolini, L; Porcelli, S; Saria, A; Serretti, A | 1 |
| Cole, SP; Craighead, WE; Dunlop, BW; Kinkead, B; LoParo, D; Mayberg, HS; Mletzko-Crowe, T; Nemeroff, CB | 1 |
| Liu, QS; Luo, T; Wei, B; Yang, YJ | 1 |
| Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
| An, J; Chen, C; Gao, HM; Li, K; Mitchell, PB; Si, TM; Wang, L; Zhang, P | 1 |
| Belzeaux, R; Blier, P; Boucekine, M; Boyer, L; Farzan, F; Fiori, LM; Foster, JA; Frey, BN; Giacobbe, P; Kennedy, SH; Lam, RW; Leri, F; Lopez, JP; MacQueen, GM; Milev, R; Müller, DJ; Parikh, SV; Rotzinger, S; Soares, CN; Turecki, G; Uher, R | 1 |
| Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E | 1 |
| Bansal, R; Hellerstein, DJ; O'Neill, J; Peterson, BS; Sawardekar, S | 1 |
| Batur, S; Dobrucali, A; Sadri, S; Sisman, G | 1 |
| Casas, M; Castells, X; Collazos, F; Eiroa-Orosa, FJ; Qureshi, A; Ramos, M; Ribases, M; Rodriguez, A; Valero, S | 1 |
| Able, SL; Cui, Z; Faries, DE; Novick, D; Shen, W | 1 |
| Štuhec, M | 1 |
| Cheng, Y; Dowsett, SA; Elpers, J; Hoog, SL | 1 |
| Amore, M; Colicchio, S; Contini, P; de Berardis, D; Escelsior, A; Fornaro, M; Fornaro, P; Martino, M; Rocchi, G | 1 |
| Berk, M; Deberdt, W; Eriksson, E; Kelin, K; Nelson, JC; Zhang, Q | 1 |
| Cohen, LS; Connors, S; Freeman, MP; Hirschberg, AM; Joffe, H; Petrillo, LF; Regan, S; Wang, B | 1 |
| Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
| Beekman, AT; Bet, PM; de Heer, EW; Dekker, J; Hakkaart-Van Roijen, L; Holwerda, TJ; Kat, F; Ringoir, L; Roth, J; van der Feltz-Cornelis, CM; van Eck van der Sluijs, JF; van Marwijk, HW | 1 |
| Hida, E; Tango, T | 2 |
| Amore, M; Colicchio, S; Contini, P; De Berardis, D; Escelsior, A; Fornaro, M; Fornaro, P; Ghio, M; Martino, M; Rocchi, G | 1 |
| Gaynor, PJ; Lipsius, S; Marangell, LB; Namiki, C; Ohara, F; Robinson, MJ; Sheehan, D; Tanaka, Y | 1 |
| Chen, Y; Faries, DE; Lipkovich, I; Liu, X; Obenchain, RL; Zagar, A | 1 |
| Malcolm, SK; Risser, RC; Robinson, MJ; Vollmer, TL | 1 |
| Arkoub, H; Augendre-Ferrante, B; Evans, D; Pamulapati, S; Perrot, S; Picard, H; Rouillon, F; Valensi, P | 1 |
| Alam, MY; Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M | 1 |
| Boulenger, JP; Loft, H; Olsen, CK | 1 |
| Liu, P; Nelson, JC; Oakes, TM; Raskin, J; Robinson, M; Shoemaker, S | 1 |
| Lenox-Smith, A; Mancini, M; Perugi, G; Schacht, A; Wade, AG | 1 |
| Beck, J; Bischof, R; Brand, S; Delini-Stula, A; Eckert, A; Hemmeter, U; Holsboer-Trachsler, E; Mikoteit, T | 2 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Bahk, WM; Woo, YS | 1 |
| Chang, HA; Hsu, CC; Kao, YC; Ku, SC; Tzeng, NS | 1 |
| Atkinson, SD; Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q | 1 |
| Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q | 1 |
| Gøtzsche, PC; Hróbjartsson, A; Jørgensen, KJ; Lundh, A; Maund, E; Schroll, J; Tendal, B | 1 |
| Gøtzsche, PC; Hróbjartsson, A; Lundh, A; Maund, E; Tendal, B | 1 |
| Doshi, P; dosReis, S; Zito, J | 1 |
| Chen, M; Han, H; Huang, Z; Wang, J; Zhang, J; Zhang, Y; Zhong, Z | 1 |
| Lobo, ED; Prakash, A; Quinlan, T | 1 |
| Gu, S; Guo, J; Luo, H; Qu, W; Tang, Q | 1 |
| Berggren, L; Gilaberte, I; Lenox-Smith, A; Pérez, V; Quail, D; Romera, I | 1 |
| Brignone, M; Ereshefsky, L; Francois, C; Lançon, C; Llorca, PM; Rive, B; Salah, S | 1 |
| Amore, M; Conio, B; Contini, P; Escelsior, A; Fornaro, M; Fornaro, P; Magioncalda, P; Marozzi, V; Martino, M; Presta, A; Rocchi, G; Sterlini, B | 1 |
| Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M; Trivedi, MH | 1 |
| Agilli, M; Aydin, FN | 1 |
| Chen, Y; Jacobson, W; Keefe, RS; Mahableshwarkar, AR; Zajecka, J | 1 |
| Bech, P; Lindberg, L; Lund, V; Lunde, M; Martiny, K; Refsgaard, E; Thougaard, B | 1 |
| Dueñas, H; Haro, JM; Hong, J; Moneta, MV; Montgomery, W; Novick, D; Peng, X | 1 |
| Douzenis, A; Gournellis, R; Michopoulos, I; Nikolaou, KN; Papageorgiou, C; Papazahos, C | 1 |
| Adams, TM; Costafreda, SG; Donati, R; Fu, CH; Horton, P; Liu, P; Maglanoc, LA; Marangell, LB; Rasenick, MM; Sankar, A | 1 |
| Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q | 1 |
| Arco, L | 1 |
| Berk, M; Dodd, S; Dueñas, H; Kelin, K; Malhi, GS; Quirk, FH; Reed, VA; Schacht, A; Williams, LJ | 1 |
| Berggren, L; Cao, H; Dueñas, HJ; Mancini, M; Sheehan, DV; Wang, J; Yue, L | 1 |
| Papakostas, GI | 1 |
| Bicer, T; Celikay, O; Gurdal, C; Kosker, M | 1 |
| Damkier, P; Ennis, ZN; Lassen, D | 1 |
| Lee, Y; McIntyre, RS | 1 |
| Baldwin, DS; Chrones, L; Florea, I; Nielsen, R; Nomikos, GG; Palo, W; Reines, E | 1 |
| Fujikoshi, S; Funai, J; Harada, E; Iwata, N; Ossipov, MH; Tokuoka, H; Wohlreich, MM | 1 |
| Kuga, A; Ozeki, A; Takahashi, H; Tokuoka, H; Tsuji, T; Wohlreich, MM; Yoshikawa, A | 1 |
| Biglia, N; Bounous, VE; Pecchio, S; Sgro, LG; Susini, T; Torta, R; Tuninetti, V | 1 |
| Citrome, L | 2 |
| Chang, CC; Hsu, WY; Ma, SP; Tsai, CJ | 1 |
| Li, G; Ma, D; Wang, X | 1 |
| Dastgheib, SA; Mowla, A; Razeghian Jahromi, L | 1 |
| Ajilore, O; Crane, NA; Hsu, DT; Kumar, A; Langenecker, SA; Mickey, BJ; Tadayonnejad, R; Zubieta, JK | 1 |
| Bai, SJ; Huang, T; Lan, XH; Qin, B; Xie, P; Xu, Y | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Hozumi, S; Sekine, A; Shimizu, T | 1 |
| Allard, P; Andersson, G; Bertilsson, G; Jonsson, U; Söderlund, A; Tham, A | 1 |
| Altamura, AC; Bertin, E; Cattaneo, D; De Gaspari, IF; Di Pace, C; Mari, D; Mauri, MC; Paletta, S; Reggiori, A; Rovera, C | 1 |
| Brawman-Mintzer, O; Dauphin, M; Gao, J; Geibel, B; Madhoo, M; McIntyre, RS; Richards, C; Sambunaris, A; Weisler, R | 1 |
| de la Cruz, AA; Díaz, S; Fried, J; Galfalvy, H; Jackson, E; Lam, P; Lewis-Fernández, R; Lucak, S; Rosario, M; Sánchez-Lacay, A; Schneier, F | 1 |
| Bhaumik, R; Crane, NA; Dion, C; Gowins, JR; Jenkins, LM; Langenecker, SA; Mickey, BJ; Zubieta, JK | 1 |
| Chekroud, AM; Gueorguieva, R; Krystal, JH | 1 |
| Chekroud, AM; Gueorguieva, R; Krumholz, HM; Krystal, JH; McCarthy, G; Trivedi, MH | 1 |
| Bansal, R; Hellerstein, DJ; Peterson, BS | 1 |
| Gourion, D | 1 |
| Andersen, HF; Lam, RW; Wade, AG | 1 |
| Häring, HU; Mörike, K; Müssig, K | 1 |
| Carvalho, LA; Gorenstein, C; Markus, RP; Moreno, R; Pariante, C | 1 |
| Deuschle, M; Englisch, S; Knopf, U; Kuwilsky, A; Scharnholz, B; Zink, M | 1 |
| Gozzi, BF; Menchetti, M; Mercolini, L; Petio, C; Raggi, MA; Saracino, MA | 1 |
| Brecht, S; Chen, A; Fava, M; Perahia, D; Walker, D; Wiltse, C | 1 |
| Griffith, JM; Hasley, JP; Severn, DG | 1 |
| Desaiah, D; Montejo, AL; Perahia, DG; Quail, D; Schatzberg, AF | 1 |
| Lin, CC | 1 |
| Chappell, AS; Detke, MJ; Fishbain, DA; Kajdasz, DK; Wernicke, J | 1 |
| Danchenko, N; Despiegel, N; Fernández, JL; François, C; Hansen, K; Wade, AG | 1 |
| Ball, S; Brecht, S; Kajdasz, D; Thase, ME | 1 |
| Deliyannides, DA; McGrath, PJ; Stewart, JW | 1 |
| Andersen, HF; Kilts, CD; Schlaepfer, TE; Wade, AG | 1 |
| Guico-Pabia, CJ; Helzner, EC; Nichols, AI; Patroneva, AL; Paul, J; Preskorn, SH | 1 |
| Adams, DH; Fijal, B; Houston, JP; Perlis, RH; Sutton, VK; Trivedi, MH | 1 |
| Guàrdia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Hinojosa-Calvo, E | 1 |
| Voznesenskaia, TG | 1 |
| Detke, MJ; Dunner, DL; Greist, JH; Hollandbeck, MS; Kornstein, SG; Mallinckrodt, CH; Meyers, AL; Whitmyer, VG; Wohlreich, MM | 1 |
| Volpe, FM | 1 |
| Gaynor, PJ; Houston, JP; Katz, MM; Meyers, AL; Prakash, A | 1 |
| Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Baldessarini, RJ; Del Casale, A; Girardi, P; Innamorati, M; Mancini, M; Mazzarini, L; Pompili, M; Serafini, G; Tatarelli, R | 1 |
| Alamo, C; Camarasa, X; García-García, P; López-Muñoz, F; Pardo, A; Seguí, J | 1 |
| Amore, M; Gianni, W; Mancini, M; Rossi, A | 1 |
| Aström, M; Brecher, M; Cutler, AJ; Feifel, D; Lazarus, A; Montgomery, SA | 1 |
| Spadone, C | 1 |
| Cerveri, G; Colasanti, A; De Gaspari, IF; Fiorentini, A; Mauri, MC; Mencacci, C; Papa, P; Valli, A; Volonteri, LS | 1 |
| Hadikusumo, B; Ng, B | 1 |
| Detke, MJ; Maina, G; Perahia, DG; Spann, ME; Thase, ME; Walker, DJ; Wang, F | 1 |
| Bourgeois, JA; Davidson, CM; Harlow, MC | 1 |
| Andersen, HF; Kornstein, SG; Larsson, S; Li, D; Mao, Y; Papakostas, GI | 1 |
| Begley, A; Dew, MA; Karp, JF; Miller, MD; Reynolds, CF; Weiner, DK | 1 |
| Corruble, E; Goldberger, C; Spann, M | 1 |
| Lai, CH | 6 |
| Guàrdia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Montelongo-Pedraza, P; Padrós Blázquez, F; Peró-Cebollero, M | 1 |
| Gartlehner, G; Gaynes, BN; Hansen, RA; Thaler, K | 1 |
| Nelson, JC | 2 |
| Biehn, TL; Sawrey, DL; Spielmans, GI | 1 |
| Aikins, D; Kasserman, S; Neumeister, A; Nishimura, C; Vojvoda, D; Walderhaug, E | 1 |
| Bitter, I; Karamustafalioglu, O; Koponen, H; Mohr, P; Sartorius, N; Seifritz, E; Svestka, J | 1 |
| Berk, M; Kelin, K; Perahia, D; Raskin, J; Sagman, D; Spann, M; Walker, D | 1 |
| Despiégel, N; Lam, RW; Lönn, SL | 1 |
| Norman, TR; Olver, JS | 1 |
| Gómez-Carbajal, L; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Joan, GO; Peña-Olvira, M; Villuendas-González, E | 1 |
| Mancini, M; Perna, G; Petralia, A; Rossi, A | 1 |
| Bradley, L; Choy, E; Clauw, DJ; Marangell, LB; Mease, P; Shoemaker, S; Wang, F; Wohlreich, MM | 1 |
| Dolder, C; Nelson, M; Stump, A | 1 |
| Hsu, YY; Lai, CH | 1 |
| Cardoner, N; Contreras-Rodríguez, O; Deus, J; Harrison, BJ; Hernández-Ribas, R; López-Solà, M; Menchón, JM; Ortiz, H; Pujol, J; Soriano-Mas, C; Vallejo, J | 1 |
| Danchenko, N; Despiegel, N; Maman, K; Marteau, F; Nordström, G | 1 |
| Able, SL; Faries, DE; Gelwicks, S; Liu, X | 1 |
| Becker, T; Grouven, U; Kaiser, T; Kerekes, MF; Koesters, M; Kreis, J; Kromp, M; Schueler, YB; Weinmann, S; Wieseler, B | 1 |
| Brecht, S; Desaiah, D; Guelfi, JD; Marechal, ES; Podhorna, J; Santini, AM | 1 |
| Desaiah, D; Detke, MJ; Kennedy, SH; Pangallo, BA; Perahia, DG; Zhang, Q | 1 |
| Bandelow, B; Wolff-Menzler, C | 1 |
| Campbell, C; Liu, J; Shi, L; Zhao, Y | 1 |
| Ansseau, M; Pitchot, W; Scantamburlo, G | 1 |
| Granger, RE; Hussain, N; Lee, AC; Lee, MS; Li, H; McIntosh, D; Raskin, J; Ruschel, S; Sagman, D | 1 |
| Detke, MJ; Montejo, AL; Perahia, DG; Spann, ME; Walker, DJ; Wang, F; Yang, CR | 1 |
| Harnett-Sheehan, K; Prakash, A; Sheehan, DV; Spann, ME; Thompson, HF | 1 |
| Chang, JP; Su, KP; Wu, CC | 1 |
| Chang, CH; Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Ameri, AA | 1 |
| Spingler, A | 1 |
| Spielmans, GI | 1 |
| Bär, KJ; Berger, S; Boettger, MK; Boettger, S; Terhaar, J; Weiss, T | 1 |
| Able, SL; Liu, X; Tepper, PG | 1 |
| Robinson, RL; Swindle, RW; Ye, W; Zhao, Y | 1 |
| Arbuckle, M; Harding, KJ; Pincus, HA; Rush, AJ; Trivedi, MH | 1 |
| Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, CJ; Weydt, P | 1 |
| Delbello, MP; Nandagopal, JJ; Strawn, JR; Whitsel, R | 1 |
| Boyce, PM; Hackett, LP; Ilett, KF | 1 |
| Chiesa, A; De Ronchi, D; Mencacci, C; Nasso, ED; Serretti, A | 1 |
| Ben-Hamadi, R; Dworak, H; Erder, MH; Ramakrishnan, K; Signorovitch, J; Wu, EQ; Yu, AP | 1 |
| Liu, X; Mullins, CD; Wang, J | 1 |
| Fuchs, D; Galfalvy, HC; Grunebaum, MF; Lapidus, M; Mann, JJ; Oquendo, MA; Postolache, TT; Sublette, ME | 1 |
| Chokka, PR; Granger, RE; Raskin, J; Sagman, D; Sheehan, DV; Walton, RJ | 1 |
| Heinloth, A; Houston, JP; Kohler, J; Ostbye, KM; Perlis, RH | 1 |
| Bandini, F; Cestari, L; Colicchio, S; Cordano, C; Escelsior, A; Fornaro, M; Martino, M; Ogliastro, C; Perugi, G; Rocchi, G | 1 |
| Lai, CH; Wu, YT | 2 |
| Gaynor, PJ; Gopal, M; Hann, D; Marangell, LB; Martinez, JM; Robinson, MJ; Zheng, W | 1 |
| Gaynor, PJ; Gopal, M; Marangell, LB; Martinez, JM; Robinson, MJ; Zheng, W | 1 |
| Bogetto, F; Maina, G; Rigardetto, S; Rosso, G | 1 |
| Eraslan, D; Ergun, BM; Genc, Y; Odabasioglu, G; Ozturk, O | 1 |
| Cui, Z; Faries, DE; Liu, X; Novick, D; Zhao, Y | 1 |
| Liu, J; Shi, L; Zhao, Y | 1 |
| Dersch, R; Voderholzer, U; Zwernemann, S | 1 |
| Cui, Z; Faries, DE; Gelwicks, S; Liu, X; Novick, D | 1 |
| Bochsler, L; Norman, TR; Olver, JS | 1 |
| Ball, T; Cui, Z; Faries, DE; Johnstone, B; Liu, X; Niu, L | 1 |
| Edwards, SE; Greist, JH; Katon, W; Kroenke, K; Marangell, LB; Martinez, JM; Meyers, AL; Shoemaker, S; Swindle, R; Thase, ME | 1 |
| Badr, MG; Brnabic, AJ; Chung, KF; Dossenbach, M; Dueñas, H; Jian, H; Lai, CH; Lee, A; Ruiz, JR; Uy-Ponio, T; Varrey, P | 1 |
| Brnabic, AJ; Casimiro-Querubin, ML; Dossenbach, M; Dueñas, H; Khaled, M; Lee, A; Montejo, AL; Prakash, S; Raskin, J | 1 |
| Brecht, S; Croenlein, J; Demyttenaere, K; Desaiah, D; Petit, C | 1 |
| Gueorguieva, R; Krystal, JH; Mallinckrodt, C | 1 |
| Baldwin, DS; Dragheim, M; Loft, H | 1 |
| Ahl, J; Kornstein, SG; Marangell, LB; Myers, AL; Oakes, TM; Prakash, A; Thase, ME | 1 |
| Dharia, S; Fijal, B; Houston, JP; Perlis, RH | 1 |
| Bullok, KE; Emslie, GJ; Kratochvil, CJ; Lobo, E; March, JS; Pangallo, BA; Prakash, A; Quinlan, T; Tamura, RN | 1 |
| Hatzinger, M; Imboden, C | 1 |
| Deberdt, W; Karamustafalioglu, O; Lipkovich, IA; Marangell, LB; Nelson, JC; Zhang, Q | 1 |
| Balzarro, B; De Ronchi, D; Pellicciari, A; Porcelli, S; Scaramelli, A; Serretti, A | 1 |
| Cao, Z; Durden, E; Happich, M; Schacht, A; Shi, N; Torres, A | 1 |
| George, T; Granger, RE; Hussain, N; Marangell, LB; Raskin, J; Zhao, GW | 1 |
| Hegerl, U; Hundemer, HP; Linden, M; Mergl, R; Quail, D; Schneider, E; Strauß, M | 1 |
| Hansen, T; Katona, C; Olsen, CK | 1 |
| Berrocoso, E; Elorza, J; Mico, JA; Perez-Caballero, L; Torres-Sanchez, S | 1 |
| Chen, X; Huang, L; Jia, Y; Ling, X; Liu, S; Wang, Y; Xu, G | 1 |
| Boess, FG; Hegerl, U; Linden, M; Mergl, R; Schacht, A; Schneider, E; Wilhelm, S | 1 |
| Aris, V; Chen, P; Fijal, B; Heinloth, AN; Houston, JP; Martinez, J; Zou, W | 1 |
| Alten, R; Bär, KJ; Häuser, W; Petzke, F; Sommer, C; Späth, M; Tölle, T; Uçeyler, N; Winkelmann, A; Winter, E | 1 |
| Kieser, M; Stucke, K | 1 |
| Binder, EB; Craighead, WE; Cubells, JF; Dunlop, BW; Goodman, MM; Kelley, ME; Kinkead, B; Kutner, M; Mayberg, HS; Nemeroff, CB; Newport, DJ; Owens, MJ; Pace, TW; Ritchie, JC; Rivera, VA; Westen, D | 1 |
| Abbar, M; Gilaberte, I; Menchón, JM; Neuhauser, D; Papen, R; Pérez, V; Picard, H; Romera, I; Schacht, A | 1 |
| Chang, JP; Wu, CC | 1 |
| Amore, M; Deberdt, W; Demyttenaere, K; Mancini, M; Quail, D; Sagman, D; Sheehan, DV | 1 |
| Contini, P; Escelsior, A; Fornaro, M; Martino, M; Rocchi, G | 1 |
| Bech, P; Lindberg, L; Lund, V; Lunde, M; Martiny, K; Refsgaard, E; Sørensen, L; Thougaard, B | 1 |
| Avanzino, L; Bonuccelli, U; Caltagirone, C; Ceravolo, R; Dell'Agnello, G; Fabbrini, G; Guadagna, M; Mancini, M; Meco, G; Morgante, F; Pierantozzi, M; Rossi, A; Ruggieri, S; Silvestrini, M; Spezia, R; Stocchi, F; Tessitore, A | 1 |
| Li, RM; Liu, ZW; Wang, C; Zhao, B | 1 |
| Greist, JH; Katona, C; Liu, P; Oakes, TM; Raskin, J; Robinson, M | 1 |
| Avena-Woods, C; Hilas, O | 1 |
| Gottlieb, B; Sacks, Z; Sharma, N; Vaidya, A | 1 |
| Dhillon, S | 1 |
| Ahl, J; Fijal, BA; Houston, JP; Kohler, J; Ostbye, K | 1 |
| Chen, Y; Jacobsen, PL; Mahableshwarkar, AR | 1 |
| Greenman, D; Kaufman, KR; Madraswala, R; Podolsky, D | 1 |
| Detke, MJ; Goldstein, DJ; Lu, Y; Mallinckrodt, C; Nemeroff, CB; Schatzberg, AF; Tran, PV | 1 |
| Ferguson, MB; Goldstein, DJ; Mallinckrodt, CH; Raskin, J | 1 |
| Leo, RJ | 1 |
| Demitrack, MA; Detke, MJ; Goldstein, DJ; Lu, Y; Mallinckrodt, C; Wiltse, C | 1 |
| Preskorn, SH | 1 |
| Detke, MJ; Mallinckrodt, CH; Raskin, J; Watkin, JG; Wohlreich, MM | 1 |
| Arnold, LM; Crofford, LJ; Detke, MJ; Goldstein, DJ; Iyengar, S; Lu, Y; Wohlreich, M | 1 |
| Brannan, SK; Brown, EB; Mallinckrodt, CH; Schatzberg, AF; Watkin, JG; Wohlreich, MM | 1 |
| Dugan, SE; Fuller, MA | 1 |
| Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN | 1 |
| Kirkpatrick, P; Waitekus, AB | 1 |
| Bitter, I; Demitrack, MA; Detke, MJ; Mallinckrodt, CH; McNamara, RK; Wiltse, CG | 1 |
| Albano, D; Zajecka, JM | 1 |
| Liu, C; Mallinckrodt, CH; Raskin, J; Watkin, JG; Wohlreich, MM | 1 |
| Detke, MJ; Kennedy, JS; Mallinckrodt, CH; Nelson, JC; Watkin, JG; Wohlreich, MM | 1 |
| Laustsen, G; Wimett, L | 1 |
| Cowen, PJ; Gama, J; Ogilvie, AD | 1 |
| Almási, J; Rihmer, Z | 1 |
| Gören, JL; Kirwin, JL | 1 |
| Bymaster, FP; Detke, MJ; Iyengar, S; Knadler, MP; Lee, TC | 1 |
| Hudson, JI; Kajdasz, DK; Mallinckrodt, CH; Martynov, OV; Watkin, JG; Wohlreich, MM | 1 |
| Konarski, JZ; McIntyre, RS | 1 |
| Brannan, SK; Delgado, PL; Detke, MJ; Mallinckrodt, CH; McNamara, RK; Tran, PV; Wang, F; Watkin, JG | 1 |
| D'Souza, DN; Detke, MJ; Dunner, DL; Kajdasz, DK; Russell, JM | 1 |
| Detke, MJ; Hirschfeld, RM; Lee, TC; Mallinckrodt, C | 1 |
| Einarson, TR; van Baardewijk, M; Vis, PM | 2 |
| Briley, M; Grady, MM; Moret, C; Stahl, SM | 1 |
| Cobb, C; Crichlow, R | 1 |
| Bettinger, TL; Crismon, ML; Hunziker, ME; Suehs, BT | 1 |
| Gahimer, J; Viktrup, L; Wernicke, JF; Wulster-Radcliffe, M; Yalcin, I | 1 |
| Desaiah, D; Haddad, PM; Kajdasz, DK; Perahia, DG | 1 |
| Andorn, AC; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Arnold, LM; D'Souza, DN; Goldstein, DJ; Iyengar, S; Pritchett, YL; Rosen, A; Wernicke, JF | 1 |
| Kozian, R | 1 |
| Burns, AM; Fava, M; Fisher, LB; Homberger, CH; Iosifescu, DV; Kinrys, G; Mischoulon, D; Papakostas, GI; Worthington, JJ | 1 |
| Bailey, RK; Mallinckrodt, CH; Plewes, JM; Watkin, JG; Wohlreich, MM | 1 |
| Keltner, NL; Lee, SI | 1 |
| Balestrieri, M; Detke, MJ; Fava, M; Perahia, D; Raskin, J; Wang, F | 1 |
| Norman, TR | 1 |
| Detke, MJ; Mallinckrodt, CH; Perahia, DG; Walker, DJ; Wang, F | 1 |
| Kajdasz, DK; Perahia, DG; Raskin, J; Tylee, A; Walker, DJ | 1 |
| Deuschle, M; Knopf, U; Kuwilsky, A; Mase, E; Zink, M | 1 |
| Das, A; Desarkar, P; Sinha, VK | 1 |
| Kornstein, SG; Mallinckrodt, CH; Stewart, DE; Watkin, JG; Wohlreich, MM | 2 |
| Hanretta, AT; Malek-Ahmadi, P | 1 |
| Carter, WP; Mallinckrodt, CH; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Eckert, L; Lançon, C | 1 |
| Cookson, J; Desaiah, D; Gilaberte, I; Kajdasz, DK | 1 |
| Kajdasz, DK; Perahia, DG; Raskin, J; Royer, MG; Walker, DJ | 1 |
| Blanco, C; Lewis-Fernández, R; Mallinckrodt, CH; Plewes, JM; Watkin, JG; Wohlreich, MM | 1 |
| Acharya, N; Baldessarini, RJ; Cavazzoni, PA; D'Souza, DN; Perahia, DG; Polzer, JP; Rosen, AS | 1 |
| Jimenez-Genchi, A | 1 |
| Krüger, S; Lindstaedt, M | 1 |
| Gahimer, J; Ossanna, MJ; Viktrup, L; Wernicke, J; Wulster-Radcliffe, M; Yalcin, I | 1 |
| Kluge, M; Schüssler, P; Steiger, A | 1 |
| Meighen, KG | 1 |
| Ballesteros, J; Callado, LF; Gutiérrez, M | 1 |
| Bauer, M; Froud, DM; Jain, R; Kajdasz, DK; Perahia, DG; Pritchett, YL; Raskin, J; Russell, JM; Spencer, KA; Thase, ME; Walker, DJ | 1 |
| Kajdasz, DK; Lledó, A; Raskin, J; Wang, F; Wernicke, J | 1 |
| Colman, SA; Harrison, GA; Hong, JP; Lee, MS; Lee, P; Liu, CY; Raskin, J; Ruschel, S; Shu, L; Wang, CY; Xu, X | 1 |
| Aboujaoude, EN; Gamel, NN; Koran, LM | 1 |
| Detke, MJ; Faries, DE; Mallinckrodt, CH; Meyers, AL; Prakash, A | 1 |
| Dinkel, JJ; Mohs, RC; Raskin, J; Rotz, BT; Sheikh, J; Siegal, A; Wiltse, CG; Xu, J | 1 |
| Aaronson, ST; Arnold, LM; Mallinckrodt, CH; Pigott, TA; Prakash, A; Wohlreich, MM | 1 |
| Florea, I; Gembert, K; Wade, A | 1 |
| Alexopoulos, GS; Bose, A; Gandhi, C; Gommoll, C; Khan, A; Li, D | 1 |
| Frampton, JE; Plosker, GL | 1 |
| Kajdasz, DK; Raskin, J; Xu, JY | 1 |
| Iosifescu, DV; Raskin, J; Sheridan, M; Wiltse, CG; Wise, TN; Xu, JY | 1 |
| Cohen, LS; Joffe, H; Koch, JK; Petrillo, LF; Soares, CN; Somley, BL; Viguera, AC | 1 |
| de Dios, C; Ezquiaga, E | 1 |
| Kirby, M; Thor, KB; Viktrup, L | 1 |
| Dunner, DL; Fava, M; Kornstein, S; Munoz, R; O'Reardon, J; Trivedi, M; Wilson, M; Wohlreich, M | 1 |
| Michel, MC | 1 |
| Detke, MJ; Mallinckrodt, CH; Prakash, A; Raskin, J; Robinson, MJ; Shelton, RC; Wohlreich, MM | 1 |
| Clayton, A; Kornstein, S; Mallinckrodt, C; Prakash, A; Wohlreich, M | 1 |
| Detke, MJ; Gilaberte, I; Hudson, JI; Perahia, DG; Wang, F; Watkin, JG | 1 |
| Hsiao, MC; Liu, CY | 1 |
| Hara, C; Ramos, MG; Rocha, FL | 1 |
| Gandhi, P; Perahia, DG; Peveler, RC; Quail, D; Walker, DJ | 1 |
| Andorn, AC; Detke, MJ; Mallinckrodt, CH; Raskin, J; Shelton, RC; Watkin, JG; Wohlreich, MM | 1 |
| Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J | 1 |
| Detke, MJ; Fava, M; Houston, JP; Mallinckrodt, CH; Prakash, A; Swindle, R | 1 |
| Brecht, S; Courtecuisse, C; Croenlein, J; Debieuvre, C; Demyttenaere, K; Desaiah, D; Petit, C; Raskin, J | 1 |
| Dunner, DL; Gonzales, JS; Greist, JH; Kornstein, SG; Mallinckrodt, CH; Meyers, AL; Whitmyer, VG; Wohlreich, MM | 1 |
| Desaiah, D; Dinkel, JJ; Katona, C; Raskin, J; Walker, DJ; Wiltse, CG | 1 |
| Liskow, BI; Parikh, AR; Tamano, EA; Thatcher, BT | 1 |
| Huguelet, P; Perroud, N; Relecom, C | 1 |
| Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR | 1 |
| Eisfeld, BS; Kennedy, SH; Ravindran, LN | 1 |
| Begley, A; Dew, MA; Karp, JF; Lenze, EJ; Miller, MD; Reynolds, CF; Whyte, EM | 1 |
| Corruble, E; Desaiah, D; Fava, M; Perahia, DG; Quail, D | 1 |
| Barzman, DH; Coffey, B; Delgado, SV; Saldaña, SN | 1 |
| Armstrong, EP; Erder, MH; Malone, DC | 1 |
| Möller, HJ; Müller, N; Riedel, M; Schennach, R | 1 |
| Demitrack, MA; Goldstein, DJ; Lu, Y; Mallinckrodt, C | 1 |
80 review(s) available for duloxetine hydrochloride and Depressive Disorder, Major
| Article | Year |
|---|---|
[The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Duloxetine Hydrochloride; Humans; Middle Aged; Randomized Controlled Trials as Topic; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Randomized Controlled Trials as Topic; Young Adult | 2021 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Vortioxetine for depression in adults.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Patient Dropouts; Piperazines; Placebos; Randomized Controlled Trials as Topic; Remission Induction; Serotonin and Noradrenaline Reuptake Inhibitors; Sulfides; Venlafaxine Hydrochloride; Vortioxetine | 2017 |
Differences in the placebo response in duloxetine and venlafaxine trials.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Placebo Effect; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2018 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Clinical Protocols; Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Registries; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2014 |
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Benzofurans; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulfides; Thiophenes; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2014 |
Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials.
Topics: Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Nocebo Effect; Thiophenes; Treatment Outcome | 2015 |
Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Disability Evaluation; Duloxetine Hydrochloride; Female; Humans; Logistic Models; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2016 |
Antidepressants and their effect on cognition in major depressive disorder.
Topics: Adult; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Executive Function; Humans; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sulfides; Vortioxetine | 2015 |
First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Cohort Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Pregnancy; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2016 |
Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI).
Topics: Antidepressive Agents; Cognition; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Learning; Mental Recall; Piperazines; Recovery of Function; Serotonin and Noradrenaline Reuptake Inhibitors; Sulfides; Vortioxetine | 2016 |
Is duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trials.
Topics: Analgesics; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Pain; Pain Measurement; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Vilazodone Hydrochloride | 2016 |
Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Piperazines; Randomized Controlled Trials as Topic; Sulfides; Treatment Outcome; Vortioxetine | 2016 |
Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
Topics: Adolescent; Antidepressive Agents; Child; Cyclopropanes; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Male; Milnacipran; Placebos; Randomized Controlled Trials as Topic; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Efficacy and tolerability of antidepressants in people aged 65 years or older with major depressive disorder - A systematic review and a meta-analysis.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Odds Ratio; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2016 |
[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].
Topics: Affect; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Mianserin; Mirtazapine; Patient Satisfaction; Personality Inventory; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Suicide Prevention; Thiophenes; Time Factors; Treatment Refusal; Venlafaxine Hydrochloride | 2008 |
Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2008 |
The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder.
Topics: Adult; Analgesia; Analgesics; Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Pain; Placebos; Randomized Controlled Trials as Topic; Thiophenes; Treatment Outcome | 2008 |
Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Wake Disorders; Thiophenes; Treatment Outcome | 2008 |
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desipramine; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Health Status; Humans; Paroxetine; Thiophenes | 2008 |
Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods.
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Placebos; Randomized Controlled Trials as Topic; Thiophenes | 2009 |
Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data.
Topics: Age Factors; Aged; Animals; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Disease Management; Duloxetine Hydrochloride; Humans; Thiophenes | 2009 |
[Severe forms of depression: the efficacy of escitalopram].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Paroxetine; Personality Inventory; Psychometrics; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Psychogenic tremor in a patient with a major depressive episode.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cognitive Behavioral Therapy; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Hospitalization; Humans; Olanzapine; Psychophysiologic Disorders; Thiophenes; Tremor | 2009 |
Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Time Factors; Venlafaxine Hydrochloride; Young Adult | 2009 |
The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Body Weight; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Nausea; Randomized Controlled Trials as Topic; Serotonin Syndrome; Thiophenes | 2009 |
Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Norepinephrine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
Continuation treatment of major depressive disorder: is there a case for duloxetine?
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Thiophenes | 2010 |
Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.
Topics: Animals; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Quality of Life; Thiophenes | 2010 |
Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine.
Topics: Adult; Affect; Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fibromyalgia; Humans; Male; Middle Aged; Pain; Pain Measurement; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Thiophenes | 2011 |
Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
Topics: Aged; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Interactions; Duloxetine Hydrochloride; Humans; Thiophenes | 2010 |
A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Duloxetine Hydrochloride; Humans; Pharmacological Phenomena; Randomized Controlled Trials as Topic; Remission Induction; Therapeutic Equivalency; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Predictors of remission with placebo using an integrated study database from patients with major depressive disorder.
Topics: Adult; Age of Onset; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Models, Theoretical; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Regression Analysis; Remission Induction; ROC Curve; Thiophenes; Treatment Outcome | 2012 |
Preclinical discovery of duloxetine for the treatment of depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Evaluation, Preclinical; Duloxetine Hydrochloride; Humans; Thiophenes | 2012 |
[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].
Topics: Amitriptyline; Analgesics; Analgesics, Opioid; Antidepressive Agents; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Cooperative Behavior; Depressive Disorder, Major; Duloxetine Hydrochloride; Fibromyalgia; gamma-Aminobutyric Acid; Germany; Humans; Interdisciplinary Communication; Off-Label Use; Patient Care Team; Pregabalin; Somatoform Disorders; Thiophenes | 2012 |
Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.
Topics: Adult; Aged; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Severity of Illness Index; Statistics as Topic; Thiophenes; Treatment Outcome | 2012 |
Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Least-Squares Analysis; Male; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2013 |
Duloxetine: a review of its use in the management of major depressive disorder in older adults.
Topics: Aged; Animals; Depressive Disorder, Major; Drug Dosage Calculations; Duloxetine Hydrochloride; Humans; Thiophenes | 2013 |
Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biological Availability; Clinical Trials as Topic; Cyclopropanes; Depressive Disorder, Major; Drug Approval; Duloxetine Hydrochloride; Humans; Metabolic Clearance Rate; Milnacipran; Morpholines; Reboxetine; Thiazepines; Thiophenes; United States | 2004 |
Duloxetine: a dual reuptake inhibitor.
Topics: Adrenergic Uptake Inhibitors; Animals; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2004 |
SNRIs in the management of acute major depressive disorder.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Placebos; Randomized Controlled Trials as Topic; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Topics: Adult; Cohort Studies; Comorbidity; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Multicenter Studies as Topic; Placebos; Randomized Controlled Trials as Topic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2005 |
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Duloxetine Hydrochloride; Humans; Placebos; Randomized Controlled Trials as Topic; Thiophenes; Treatment Outcome | 2005 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Drug Interactions; Duloxetine Hydrochloride; Humans; Middle Aged; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2005 |
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Microdialysis; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2005 |
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Body Weight; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sexual Behavior; Thiophenes | 2005 |
Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Economics, Pharmaceutical; Humans; Pain; Pain Measurement; Thiophenes | 2005 |
Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Placebos; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2005 |
Time course of depression-symptom improvement during treatment with duloxetine.
Topics: Adult; Antidepressive Agents; Back Pain; Depressive Disorder, Major; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Guilt; Humans; Hypochondriasis; Male; Pain Measurement; Randomized Controlled Trials as Topic; Remission Induction; Sexual Dysfunctions, Psychological; Shoulder Pain; Sleep Initiation and Maintenance Disorders; Somatoform Disorders; Surveys and Questionnaires; Thiophenes; Time Factors | 2005 |
Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Cost of Illness; Cost-Benefit Analysis; Cyclohexanols; Decision Trees; Depressive Disorder, Major; Duloxetine Hydrochloride; Economics, Pharmaceutical; Health Care Costs; Humans; Middle Aged; Models, Econometric; Norepinephrine; Ontario; Outpatients; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; In Vitro Techniques; Milnacipran; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride; Vesicular Monoamine Transport Proteins | 2005 |
Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
Topics: Adult; Cyclohexanols; Data Collection; Delayed-Action Preparations; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Patient Dropouts; Randomized Controlled Trials as Topic; Review Literature as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Biological Availability; Depressive Disorder, Major; Drug Interactions; Duloxetine Hydrochloride; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Multicenter Studies as Topic; Nausea; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2005 |
Safety and adverse event profile of duloxetine.
Topics: Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Diabetic Neuropathies; Dose-Response Relationship, Drug; Drug Interactions; Duloxetine Hydrochloride; Half-Life; Humans; Selective Serotonin Reuptake Inhibitors; Thiophenes; Urinary Incontinence, Stress | 2005 |
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Long-Term Care; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Thiophenes | 2005 |
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2006 |
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Black or African American; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Thiophenes; Treatment Outcome; White People | 2006 |
Prospects for the treatment of depression.
Topics: Acetamides; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Hypnotics and Sedatives; Nerve Growth Factors; Selective Serotonin Reuptake Inhibitors; Substance P; Thiophenes; Vasopressins | 2006 |
Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Patient Dropouts; Randomized Controlled Trials as Topic; Sex Factors; Thiophenes | 2006 |
Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Health Status; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pain Measurement; Placebos; Psychiatric Status Rating Scales; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Factors; Surveys and Questionnaires; Thiophenes; Treatment Outcome | 2006 |
Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Regression Analysis; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Hispanic or Latino; Humans; Multicenter Studies as Topic; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Thiophenes; Treatment Outcome; White People | 2006 |
Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
Topics: Adult; Antidepressive Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Incidence; Male; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Suicide; Thinking; Thiophenes; Time Factors | 2006 |
An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Humans; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Thiophenes; Treatment Outcome; Withholding Treatment | 2007 |
An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Topics: Adrenergic Uptake Inhibitors; Anxiety Disorders; Cardiovascular Diseases; Depressive Disorder, Major; Diabetic Neuropathies; Duloxetine Hydrochloride; Fibromyalgia; Humans; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Urinary Incontinence | 2007 |
Duloxetine: a review of its use in the treatment of major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Duloxetine Hydrochloride; Humans; Randomized Controlled Trials as Topic; Thiophenes | 2007 |
Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Diabetic Neuropathies; Duloxetine Hydrochloride; Female; Humans; Male; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiophenes; Treatment Outcome; Urinary Incontinence, Stress | 2007 |
Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2007 |
Duloxetine in the treatment of major psychiatric and neuropathic disorders.
Topics: Antidepressive Agents; Anxiety; Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Pain; Peripheral Nervous System Diseases; Practice Patterns, Physicians'; Thiophenes; Treatment Outcome; Urinary Incontinence, Stress | 2008 |
Compelling or irrelevant? Using number needed to treat can help decide.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Data Interpretation, Statistical; Depressive Disorder, Major; Dibenzothiazepines; Duloxetine Hydrochloride; Evidence-Based Medicine; Humans; Outcome Assessment, Health Care; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Schizophrenia; Secondary Prevention; Thiophenes; Treatment Outcome | 2008 |
130 trial(s) available for duloxetine hydrochloride and Depressive Disorder, Major
| Article | Year |
|---|---|
Efficacy and Safety of Duloxetine in Children and Adolescents with Major Depressive Disorder in Japan: A Randomized Double-Blind Placebo-Controlled Clinical Trial Followed by an Open-Label Long-Term Extension Trial.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Humans; Japan; Treatment Outcome | 2022 |
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.
Topics: Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Female; Humans; Magnetic Resonance Imaging; Psychotherapy | 2023 |
A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Duloxetine Hydrochloride; Humans; Treatment Outcome | 2023 |
Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder.
Topics: Adult; Child; Depressive Disorder, Major; Duloxetine Hydrochloride; East Asian People; Humans; Japan | 2023 |
Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence.
Topics: Brain; Brain Mapping; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Magnetic Resonance Imaging; Prospective Studies | 2023 |
The therapeutic alliance - its impact on antidepressant therapies in major depressive conditions and on the overall health.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Health Status; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Therapeutic Alliance | 2019 |
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: Study protocol for a randomized, parallel-group, non-inferiority trial.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Equivalence Trials as Topic; Humans; Outpatients | 2019 |
The Effect of Food on the Single-Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine.
Topics: Adult; Anxiety Disorders; Biological Availability; Cross-Over Studies; Depressive Disorder, Major; Diabetic Neuropathies; Drug Compounding; Duloxetine Hydrochloride; Fasting; Female; Food; Food-Drug Interactions; Humans; Male; Middle Aged; Safety; Serotonin and Noradrenaline Reuptake Inhibitors; Therapeutic Equivalency; Treatment Outcome | 2020 |
Gray matter reorganization underpinnings of antidepressant treatment of persistent depressive disorder.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Gray Matter; Humans; Magnetic Resonance Imaging | 2021 |
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Japan; Outpatients; Treatment Outcome | 2021 |
Eight-week antidepressant treatment reduces functional connectivity in first-episode drug-naïve patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Cerebral Cortex; Connectome; Default Mode Network; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Treatment Outcome; Young Adult | 2021 |
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Depressive Disorder, Major; Dominance, Cerebral; Duloxetine Hydrochloride; Female; Gyrus Cinguli; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Outcome Assessment, Health Care; Prefrontal Cortex; Psychiatric Status Rating Scales; Young Adult | 2017 |
Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Preference; Psychiatric Status Rating Scales; Psychometrics; Treatment Outcome | 2017 |
Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Topics: Antidepressive Agents; Biomarkers; Citalopram; Clinical Decision-Making; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Humans; MicroRNAs; Psychiatric Status Rating Scales; ROC Curve; Treatment Outcome | 2017 |
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.
Topics: Adult; Aged; Animals; Antidepressive Agents; Biomarkers; Brain; Computational Biology; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Gene Expression Regulation; HEK293 Cells; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; MicroRNAs; Middle Aged; Wnt Signaling Pathway; Young Adult | 2017 |
Selective Serotonergic (SSRI) Versus Noradrenergic (SNRI) Reuptake Inhibitors with and without Acetylsalicylic Acid in Major Depressive Disorder.
Topics: Antidepressive Agents; Aspirin; Citalopram; Cyclooxygenase Inhibitors; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Selective Serotonin Reuptake Inhibitors | 2017 |
Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Self Report; Vortioxetine; Young Adult | 2018 |
Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Topics: Adult; Aged; Cognition; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Outpatients; Psychometrics; Psychotherapy; Self Report; Surveys and Questionnaires; Vortioxetine; Young Adult | 2018 |
5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial.
Topics: Adult; Alleles; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; RNA, Messenger; Serotonin Plasma Membrane Transport Proteins; Time Factors; Treatment Outcome | 2018 |
Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.
Topics: Adult; Apoptosis; Biomarkers; Circulating MicroRNA; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Sequence Analysis, RNA; Serotonin and Noradrenaline Reuptake Inhibitors; Signal Transduction | 2019 |
Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Duloxetine Hydrochloride; Female; Humans; Male; Treatment Failure | 2019 |
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Genetic Markers; Humans; Male; Microfilament Proteins; MicroRNAs; Middle Aged; Nerve Tissue Proteins; Prognosis; RNA, Messenger; Stathmin; Suicidal Ideation; Young Adult | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial.
Topics: Adult; Antidepressive Agents; Aspartic Acid; Brain; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Treatment Outcome | 2019 |
NGF serum levels variations in major depressed patients receiving duloxetine.
Topics: Adaptation, Psychological; Adult; Biomarkers; Depressive Disorder, Major; Drug Resistance; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Nerve Growth Factor; Neuronal Plasticity; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Stress, Psychological; Sympathomimetics; Thiophenes; Time Factors; Treatment Outcome | 2013 |
Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Placebo Effect; Placebos; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Hot Flashes; Humans; Menopause; Middle Aged; Patient Selection; Severity of Illness Index; Thiophenes | 2013 |
Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled m
Topics: Adaptation, Psychological; Antidepressive Agents; Chronic Pain; Cost-Benefit Analysis; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Patient Care Team; Primary Health Care; Quality of Life; Referral and Consultation; Research Design; Self Care; Thiophenes | 2013 |
Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine.
Topics: Adult; Analgesics; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Statistics as Topic; Thiophenes | 2013 |
A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis.
Topics: Adolescent; Adult; Analgesics; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Thiophenes; Treatment Outcome | 2014 |
Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Contraindications; Depressive Disorder, Major; Drug Utilization; Duloxetine Hydrochloride; Female; France; Humans; Male; Middle Aged; Thiophenes | 2014 |
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Suicidal Ideation; Sulfides; Thiophenes; Treatment Outcome; Vortioxetine; Weight Gain; Young Adult | 2014 |
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Headache; Humans; Internationality; Male; Middle Aged; Nausea; Piperazines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sulfides; Thiophenes; Treatment Outcome; Vortioxetine; Young Adult | 2014 |
Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Topics: Age of Onset; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Pain; Psychiatric Status Rating Scales; Thiophenes | 2014 |
High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression.
Topics: Adult; Antidepressive Agents; Blood Chemical Analysis; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Prognosis; Prospective Studies; Psychiatric Status Rating Scales; Switzerland; Thiophenes; Time Factors; Treatment Outcome | 2014 |
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Suicidal Ideation; Suicide; Thiophenes; Treatment Outcome | 2014 |
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Suicidal Ideation; Suicide; Thiophenes; Treatment Outcome | 2014 |
Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
Topics: Adult; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Combinations; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Quality of Life; Sleep Wake Disorders; Somatoform Disorders; Thiophenes | 2014 |
A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Electrocardiography; Fatigue; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Suicidal Ideation; Sulfides; Vortioxetine; Young Adult | 2015 |
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Cognition Disorders; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Sulfides; Surveys and Questionnaires; Treatment Outcome; Vortioxetine; Young Adult | 2015 |
Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression.
Topics: Adult; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Chronotherapy; Duloxetine Hydrochloride; Exercise; Exercise Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phototherapy; Self-Assessment; Sleep; Treatment Outcome | 2015 |
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Suicidal Ideation | 2015 |
Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Genetic Variation; Humans; Interleukin-1beta; Interleukin-2; Interleukin-6; Male; Middle Aged; Receptors, GABA; Treatment Outcome | 2015 |
Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Logistic Models; Male; Middle Aged; Treatment Outcome | 2016 |
Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Breast Neoplasms; Cancer Survivors; Citalopram; Depressive Disorder, Major; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Hot Flashes; Humans; Medication Adherence; Middle Aged; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Tablets; Treatment Outcome | 2018 |
Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychomotor Performance; Sertraline; Sexual Dysfunction, Physiological; Suicidal Ideation; Treatment Outcome | 2016 |
Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.
Topics: Age Factors; Aged; Aged, 80 and over; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Male; Predictive Value of Tests; Psychiatric Status Rating Scales; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2016 |
Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Least-Squares Analysis; Lisdexamfetamine Dimesylate; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Meta-Analysis as Topic; Middle Aged; Patient Dropouts; Placebo Effect; Protective Factors; Recurrence; Severity of Illness Index; Time Factors; Treatment Outcome; Withholding Treatment | 2017 |
Evidence for neuroplastic compensation in the cerebral cortex of persons with depressive illness.
Topics: Adult; Antidepressive Agents; Brain; Cerebral Cortex; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Dysthymic Disorder; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Neuronal Plasticity; Placebo Effect; Treatment Outcome | 2018 |
Effect of antidepressants on melatonin metabolite in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Hypericum; Male; Melatonin; Middle Aged; Plant Extracts; Severity of Illness Index; Thiophenes; Treatment Outcome | 2009 |
Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Prospective Studies; Thiophenes | 2009 |
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Predictive Value of Tests; Prevalence; Prospective Studies; Recurrence; Severity of Illness Index; Thiophenes | 2009 |
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression.
Topics: Activities of Daily Living; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Europe; Female; Health Surveys; Humans; Male; Middle Aged; Pain; Pain Measurement; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Thiophenes; Time Factors; Treatment Outcome | 2009 |
Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Topics: Absenteeism; Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Sick Leave; Surveys and Questionnaires; Thiophenes; United Kingdom; Young Adult | 2008 |
Is duloxetine effective treatment for depression with atypical features?
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2008 |
Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Thiophenes; Treatment Outcome | 2009 |
Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.
Topics: Adult; Catechol O-Methyltransferase; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Genome-Wide Association Study; Genotype; Humans; Male; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2009 |
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Citalopram; Cognition; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Memory; Neuropsychological Tests; Neurotransmitter Uptake Inhibitors; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thinking; Thiophenes | 2009 |
A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
Topics: Adolescent; Adult; Antidepressive Agents; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Personality Inventory; Prospective Studies; Psychometrics; Retreatment; Thiophenes; Treatment Outcome; Young Adult | 2008 |
An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache.
Topics: Adolescent; Adult; Antidepressive Agents; Brazil; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Headache Disorders; Humans; Male; Middle Aged; Pain Measurement; Personality Inventory; Prognosis; Quality of Life; Thiophenes | 2008 |
Early symptom change prediction of remission in depression treatment.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2009 |
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2010 |
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes | 2009 |
Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial.
Topics: Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Prevalence; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sex Distribution; Thiophenes | 2009 |
Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder.
Topics: Combat Disorders; Comorbidity; Depressive Disorder, Major; Dreams; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Psychiatric Status Rating Scales; Stress Disorders, Post-Traumatic; Thiophenes; Time Factors; Treatment Outcome; Veterans; Warfare | 2010 |
Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Secondary Prevention; Thiophenes; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Hospitalization; Humans; Male; Middle Aged; Personality Inventory; Psychometrics; Suicidal Ideation; Thiophenes | 2011 |
Attributes of response in depressed patients switched to treatment with duloxetine.
Topics: Adult; Affective Symptoms; Antidepressive Agents; Chronic Pain; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2011 |
Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Male; Psychiatric Status Rating Scales; Sexual Behavior; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Thiophenes | 2011 |
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
Topics: Antidepressive Agents; Anxiety Disorders; Comorbidity; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Outpatients; Placebos; Psychiatric Status Rating Scales; Psychometrics; Thiophenes; Time Factors; Treatment Outcome | 2011 |
Pseudohypoalgesia on the skin: a novel view on the paradox of pain perception in depression.
Topics: Adult; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Hot Temperature; Humans; Male; Middle Aged; Pain; Pain Measurement; Pain Perception; Pain Threshold; Skin Physiological Phenomena; Thiophenes | 2011 |
Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Thiophenes; Treatment Outcome | 2011 |
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Norepinephrine; Remission Induction; Serotonin; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine.
Topics: Adult; Depressive Disorder, Major; Drug Substitution; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2011 |
Duloxetine's modest short-term influences in subcortical structures of first episode drug-naïve patients with major depressive disorder and panic disorder.
Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Panic Disorder; Psychiatric Status Rating Scales; Statistics as Topic; Thiophenes | 2011 |
Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Pain; Puerto Rico; Remission Induction; Thiophenes; Time Factors; United States | 2011 |
A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Remission Induction; Thiophenes; Time Factors | 2011 |
A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Single-Blind Method; Thiophenes | 2012 |
A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Disability Evaluation; Drugs, Generic; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outpatients; Prospective Studies; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Time Factors; Treatment Outcome; United States | 2012 |
Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.
Topics: Adult; Antidepressive Agents; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Linear Models; Male; Patient Dropouts; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome | 2011 |
A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Topics: Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Logistic Models; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Reference Values; Sulfides; Thiophenes; Treatment Outcome; Vortioxetine | 2012 |
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Models, Statistical; Psychiatric Status Rating Scales; Recovery of Function; Thiophenes; Treatment Outcome | 2012 |
An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression.
Topics: Adolescent; Antidepressive Agents; Blood Pressure; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Male; Psychiatric Status Rating Scales; Severity of Illness Index; Suicidal Ideation; Thiophenes; Treatment Outcome | 2012 |
Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
Topics: Adult; Aged; Analysis of Variance; Apathy; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2012 |
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Sulfides; Thiophenes; Vortioxetine | 2012 |
Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment.
Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Hippocampus; Humans; Hydrocortisone; Magnetic Resonance Spectroscopy; Male; Middle Aged; Thiophenes; Young Adult | 2012 |
Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.
Topics: Adult; Antidepressive Agents; Catechol O-Methyltransferase; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Models, Genetic; Norepinephrine Plasma Membrane Transport Proteins; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1A; Surveys and Questionnaires; Thiophenes; Treatment Outcome | 2012 |
Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Biomarkers; Brain; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Genetic Testing; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Personality; Predictive Value of Tests; Remission Induction; Research Design; Thiophenes; Treatment Outcome; Young Adult | 2012 |
Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Substitution; Duloxetine Hydrochloride; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Pain; Pain Measurement; Thiophenes; Treatment Outcome; Young Adult | 2012 |
A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine.
Topics: Adult; Aged; Antidepressive Agents; Combined Modality Therapy; Denmark; Depressive Disorder, Major; Duloxetine Hydrochloride; Exercise; Female; Humans; Logistic Models; Male; Middle Aged; Phototherapy; Prospective Studies; Seasons; Single-Blind Method; Sleep Phase Chronotherapy; Thiophenes | 2012 |
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Thiophenes; Treatment Outcome | 2012 |
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Placebos; Sexual Dysfunction, Physiological; Suicidal Ideation; Sulfides; Thiophenes; Treatment Outcome; Vortioxetine | 2013 |
Duloxetine in the long-term treatment of major depressive disorder.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antidepressive Agents; Chronic Disease; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Long-Term Care; Male; Middle Aged; Personality Inventory; Thiophenes; Treatment Outcome | 2003 |
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
Topics: Adult; Analysis of Variance; Confidence Intervals; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Logistic Models; Male; Middle Aged; Paroxetine; Sleep Initiation and Maintenance Disorders; Thiophenes | 2004 |
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Topics: Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fibromyalgia; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Sex Factors; Thiophenes; Treatment Outcome | 2004 |
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Topics: Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Placebos; Severity of Illness Index; Thiophenes; Treatment Outcome | 2005 |
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Europe; Female; Fluoxetine; Humans; Male; Middle Aged; Nausea; Paroxetine; Prevalence; Severity of Illness Index; Sex Factors; Thiophenes; Time Factors; United States | 2004 |
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Weight; Cardiovascular Diseases; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Electrocardiography; Female; Hemodynamics; Humans; Longitudinal Studies; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Thiophenes | 2004 |
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
Topics: Adult; Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Incidence; Male; Middle Aged; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Sexual Dysfunctions, Psychological; Thiophenes; Treatment Outcome | 2005 |
A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fibromyalgia; Humans; Middle Aged; Pain Measurement; Placebo Effect; Quality of Life; Thiophenes; Treatment Outcome; United States; Women's Health | 2005 |
Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Long-Term Care; Male; Middle Aged; Recurrence; Thiophenes; Treatment Outcome | 2006 |
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Topics: Adult; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Mass Screening; Middle Aged; Paroxetine; Placebo Effect; Prevalence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2006 |
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes; Treatment Outcome | 2006 |
Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Duloxetine Hydrochloride; Female; Humans; Long-Term Care; Male; Middle Aged; Personality Inventory; Thiophenes; Treatment Outcome | 2007 |
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2006 |
Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes; Treatment Outcome | 2006 |
Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Electroencephalography; Female; Humans; Male; Middle Aged; Polysomnography; Prospective Studies; Psychiatric Status Rating Scales; Sleep Stages; Sleep, REM; Thiophenes | 2007 |
A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Brazil; China; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Heart Rate; Humans; Korea; Male; Middle Aged; Pain; Pain Measurement; Paroxetine; Psychiatric Status Rating Scales; Taiwan; Thiophenes; Weight Gain | 2007 |
Duloxetine treatment of dysthymia and double depression: an open-label trial.
Topics: Adult; Depressive Disorder, Major; Duloxetine Hydrochloride; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2007 |
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Topics: Age Factors; Aged; Antidepressive Agents; Back Pain; Cognition Disorders; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Geriatric Assessment; Humans; Male; Neuropsychological Tests; Pain; Pain Measurement; Placebos; Psychiatric Status Rating Scales; Secondary Prevention; Thiophenes; Treatment Outcome | 2007 |
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Placebos; Remission Induction; Thiophenes; Treatment Outcome | 2007 |
A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Tolerance; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Thiophenes | 2007 |
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes | 2007 |
Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Thiophenes; Time Factors | 2008 |
The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Arthritis; Cardiovascular Diseases; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Pain; Pain Measurement; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.
Topics: Adult; Anxiety; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Hot Flashes; Humans; Middle Aged; Pain; Postmenopause; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Sleep Wake Disorders; Thiophenes; Treatment Outcome | 2007 |
Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Long-Term Care; Male; Middle Aged; Patient Dropouts; Personality Inventory; Psychometrics; Recurrence; Substance Withdrawal Syndrome; Thiophenes; Treatment Outcome | 2008 |
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sexual Behavior; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Thiophenes | 2007 |
Duloxetine in the treatment of major depressive disorder: an open-label study.
Topics: Chronic Disease; Depressive Disorder, Major; Disability Evaluation; Duloxetine Hydrochloride; Humans; Quality of Life; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Thiophenes; Treatment Outcome | 2007 |
A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Personality Inventory; Referral and Consultation; Telephone; Thiophenes; Treatment Outcome | 2008 |
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Severity of Illness Index; Thiophenes | 2007 |
A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Outpatients; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2007 |
Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Thiophenes | 2008 |
Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
Topics: Age of Onset; Aged; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Duloxetine Hydrochloride; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Thiophenes; Treatment Outcome | 2008 |
Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques.
Topics: Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2008 |
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Pressure; Body Weight; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2002 |
162 other study(ies) available for duloxetine hydrochloride and Depressive Disorder, Major
| Article | Year |
|---|---|
Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.
Topics: Animals; Depressive Disorder, Major; Duloxetine Hydrochloride; Mice; Microsomes, Liver; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors | 2022 |
The Antidepressant Duloxetine Inhibits Platelet Function and Protects against Thrombosis.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Hemostasis; Humans; Mice; Norepinephrine; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Serotonin; Serotonin Antagonists; Thrombosis | 2022 |
Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants.
Topics: Adolescent; Antidepressive Agents; Artificial Intelligence; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Fluoxetine; Humans; Machine Learning; Treatment Outcome | 2022 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal.
Topics: Animals; Biological Availability; Depressive Disorder, Major; Drug Carriers; Drug Delivery Systems; Duloxetine Hydrochloride; Gels; Particle Size; Rats | 2022 |
Mixed lymphocytic and collagenous inflammation of the entire gastrointestinal tract under therapy with serotonin and norepinephrine reuptake inhibitors.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Gastrointestinal Tract; Humans; Inflammation; Middle Aged; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2022 |
Determination of Patient Adherence for Duloxetine in Urine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Creatinine; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Norepinephrine; Patient Compliance; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiophenes; Young Adult | 2022 |
Duloxetine ameliorates lipopolysaccharide-induced microglial activation by suppressing iNOS expression in BV-2 microglial cells.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Depressive Disorder, Major; Duloxetine Hydrochloride; Lipopolysaccharides; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Norepinephrine; Proto-Oncogene Proteins c-akt; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors | 2022 |
High-content imaging of human hepatic spheroids for researching the mechanism of duloxetine-induced hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Depressive Disorder, Major; Duloxetine Hydrochloride; Fatty Liver; Humans | 2022 |
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Topics: Animals; Central Nervous System Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Mice; Mice, Knockout; Propranolol; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors | 2023 |
Duloxetine Does not Affect Vascular Endothelial Growth Factor Plasma Levels in Patients with First-Episode, Drug-Naïve Major Depression.
Topics: Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2023 |
The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression.
Topics: Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Depression; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Duloxetine Hydrochloride; Humans; Polymorphism, Genetic | 2023 |
Antidepressant duloxetine hydrochloride protects against ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation.
Topics: Animals; Antidepressive Agents; Cell Differentiation; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Mice; Osteoclasts; Osteogenesis; Ovariectomy; RANK Ligand | 2023 |
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity.
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Network Meta-Analysis; Paroxetine; Publication Bias; Reproducibility of Results; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder.
Topics: Adult; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; MicroRNAs; Middle Aged; Polymorphism, Genetic; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2020 |
Topological network mechanisms of clinical response to antidepressant treatment in drug-naive major depressive disorder.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Nerve Net | 2021 |
Duloxetine versus 'active' placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Meta-Analysis as Topic; Quality of Life; Randomized Controlled Trials as Topic; Suicidal Ideation; Systematic Reviews as Topic | 2021 |
Reduced serum VGF levels were reversed by antidepressant treatment in depressed patients.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nerve Growth Factors; Outcome Assessment, Health Care | 2017 |
Genome-wide association studies of placebo and duloxetine response in major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; CD56 Antigen; Depressive Disorder, Major; DNA-Binding Proteins; Double-Blind Method; Duloxetine Hydrochloride; Female; Genome-Wide Association Study; Genotype; Humans; Male; Middle Aged; Nerve Tissue Proteins; Placebos; Transcription Factors; Young Adult | 2018 |
Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome | 2018 |
GWAS-based machine learning approach to predict duloxetine response in major depressive disorder.
Topics: Adult; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Prognosis; Sensitivity and Specificity; Serotonin and Noradrenaline Reuptake Inhibitors; Support Vector Machine | 2018 |
How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients?
Topics: Adolescent; Adult; Antidepressive Agents; Cross-Sectional Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Intraocular Pressure; Male; Middle Aged; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2018 |
Drug-induced movement disorder and confusion associated with duloxetine.
Topics: Antidepressive Agents; Brain; Confusion; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Movement Disorders | 2018 |
Multidimensional imaging techniques for prediction of treatment response in major depressive disorder.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Photic Stimulation; Predictive Value of Tests; Psychomotor Performance; Treatment Outcome | 2019 |
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
Topics: Adult; Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cognitive Behavioral Therapy; Depressive Disorder, Major; Disease Progression; Duloxetine Hydrochloride; Female; Humans; Latent Class Analysis; Male; Middle Aged; Receptor, Serotonin, 5-HT2A; Receptors, Kainic Acid; Serotonin Plasma Membrane Transport Proteins; Tacrolimus Binding Proteins; Treatment Outcome; Young Adult | 2018 |
[With the Characteristics of Chronic Pain Patients, Can the Therapeutic Effect of Antidepressant Duloxetine be Predicted?].
Topics: Adult; Aged; Antidepressive Agents; Anxiety; Chronic Pain; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies | 2016 |
Duloxetine plasma level and antidepressant response.
Topics: Administration, Oral; Ambulatory Care; Antidepressive Agents; Biological Variation, Individual; Depressive Disorder, Major; Drug Monitoring; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2019 |
Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report.
Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Galactorrhea; Humans; Hyperprolactinemia; Menstruation Disturbances; Prolactin; Receptors, Dopamine D2 | 2019 |
Duloxetine effects on striatal resting-state functional connectivity in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Corpus Striatum; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Rest; Young Adult | 2019 |
Collagenous colitis and ileitis under treatment with duloxetine.
Topics: Aged; Antidepressive Agents; Biopsy; Chronic Disease; Colitis, Collagenous; Colon; Colonoscopy; Depressive Disorder, Major; Diarrhea; Duloxetine Hydrochloride; Female; Humans; Ileitis; Ileum; Recurrence; Thiophenes; Treatment Outcome; Withholding Treatment | 2012 |
Effectiveness and tolerability of duloxetine in 2 different ethnic samples: a prospective observational cohort study.
Topics: Adult; American Indian or Alaska Native; Antidepressive Agents; Cohort Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Ethnicity; Female; Humans; Male; Middle Aged; Prospective Studies; Spain; Thiophenes; Treatment Outcome; White People | 2013 |
Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Health Expenditures; Humans; Insurance, Health; Longitudinal Studies; Male; Middle Aged; Residence Characteristics; Retrospective Studies; Sex Factors; Thiophenes; Young Adult | 2013 |
Duloxetine-induced life-threatening long QT syndrome.
Topics: Antidepressive Agents; Arrhythmia, Sinus; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Long QT Syndrome; Middle Aged; Thiophenes | 2013 |
Duloxetine and pregnancy outcomes: safety surveillance findings.
Topics: Abortion, Spontaneous; Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Duloxetine Hydrochloride; Female; Humans; Infant; Infant, Newborn; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
Topics: Antidepressive Agents; Confidence Intervals; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Endpoint Determination; Humans; Models, Statistical; Monte Carlo Method; Placebos; Randomized Controlled Trials as Topic; Research Design; Sample Size; Thiophenes; Treatment Outcome | 2013 |
VEGF plasma level variations in duloxetine-treated patients with major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Thiophenes; Vascular Endothelial Growth Factor A | 2013 |
Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder.
Topics: Adolescent; Adult; Age Factors; Caregivers; Cluster Analysis; Cyclohexanols; Data Mining; Decision Making; Delayed-Action Preparations; Depressive Disorder, Major; Drug Costs; Duloxetine Hydrochloride; Female; Health Education; Humans; Insurance Claim Reporting; Male; Middle Aged; Observational Studies as Topic; Outcome and Process Assessment, Health Care; Statistics as Topic; Statistics, Nonparametric; Thiophenes; Venlafaxine Hydrochloride; Young Adult | 2013 |
Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Databases, Factual; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Patient Selection; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Signal Detection, Psychological; Thiophenes; Young Adult | 2014 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
Burning paresthesia related to duloxetine therapy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Paresthesia; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2014 |
Duloxetine may enhance control of pain related to bladder trauma.
Topics: Analgesics; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Pelvic Pain; Thiophenes; Treatment Outcome; Young Adult | 2014 |
Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.
Topics: Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Clinical Coding; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Thiophenes | 2014 |
Digging for data on harms in duloxetine trials.
Topics: Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Clinical Coding; Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Thiophenes | 2014 |
Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Antiemetics; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Nausea; Olanzapine; Thiophenes; Treatment Outcome; Vomiting; Young Adult | 2014 |
Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.
Topics: Administration, Oral; Adolescent; Age Factors; Antidepressive Agents; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Humans; Models, Biological; Randomized Controlled Trials as Topic; Thiophenes | 2014 |
Individual residual symptoms and functional impairment in patients with depression.
Topics: Adult; Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Sleep Wake Disorders; Thiophenes | 2014 |
BDNF plasma levels variations in major depressed patients receiving duloxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Time Factors; Young Adult | 2015 |
Methodological approach to brain-derived neurotrophic factor plasma levels in major depressed patients receiving duloxetine.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male | 2015 |
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Pain; Paroxetine; Prospective Studies; Quality of Life; Regression Analysis; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome | 2016 |
Restless legs syndrome associated with the combined use of duloxetine plus paroxetine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Paroxetine; Restless Legs Syndrome | 2015 |
Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine.
Topics: Adult; Brain; Brain Mapping; Depressive Disorder, Major; Duloxetine Hydrochloride; Echo-Planar Imaging; Emotions; Facial Expression; Female; Functional Neuroimaging; Humans; Imaging, Three-Dimensional; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Stroop Test; Thiophenes | 2015 |
A case study in treating chronic comorbid obsessive-compulsive disorder and depression with behavioral activation and pharmacotherapy.
Topics: Amitriptyline; Antidepressive Agents; Behavior Therapy; Chronic Disease; Clomipramine; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Lithium Compounds; Male; Middle Aged; Obsessive-Compulsive Disorder; Treatment Outcome | 2015 |
Improved Alertness Is Associated with Early Increase in Serum Brain-Derived Neurotrophic Factor and Antidepressant Treatment Outcome in Major Depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests | 2015 |
A case of retrobulbar optic neuritis caused by duloxetine.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Evoked Potentials, Visual; Eye; Female; Humans; Methylprednisolone; Optic Neuritis; Prednisone; Visual Acuity; Visual Fields | 2016 |
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sulfides; Venlafaxine Hydrochloride; Vortioxetine; Young Adult | 2016 |
Delirium associated with concomitant use of duloxetine and bupropion in an elderly patient.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Cytochrome P-450 CYP2D6 Inhibitors; Delirium; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Duloxetine Hydrochloride; Humans; Male; Treatment Outcome | 2017 |
Pharmacological modulation of pulvinar resting-state regional oscillations and network dynamics in major depression.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cerebral Cortex; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Male; Pulvinar; Rest | 2016 |
Influence of painful physical symptoms in the treatment of Japanese patients with melancholic major depressive disorder: A prospective cohort study.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Comorbidity; Cyclopropanes; Depressive Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Milnacipran; Pain; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2016 |
An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Serotonin and Noradrenaline Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI.
Topics: Adult; Antidepressive Agents; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Oxygen; Predictive Value of Tests; Treatment Outcome | 2017 |
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Bupropion; Citalopram; Cluster Analysis; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Randomized Controlled Trials as Topic; Sleep; Syndrome; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2017 |
Severe and symptomatic hyponatremia following duloxetine treatment.
Topics: Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Hyponatremia; Severity of Illness Index; Thiophenes | 2009 |
Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines.
Topics: Affect; Aged; Antidepressive Agents; Chromatography, High Pressure Liquid; Confusion; Depressive Disorder, Major; Drug Interactions; Drug Overdose; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Gastric Lavage; Humans; Life Change Events; Metabolic Clearance Rate; Suicide, Attempted; Thiophenes | 2009 |
Measurement of pain and medication effect in a study of duloxetine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Pain; Pain Measurement; Prevalence; Severity of Illness Index; Thiophenes | 2008 |
Duloxetine treatment of social anxiety disorder with comorbid major depression.
Topics: Adrenergic Uptake Inhibitors; Anxiety Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2008 |
[Chronic pain and depression].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Chronic Disease; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Pain; Prevalence; Thiophenes | 2008 |
Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2010 |
Serotonin syndrome induced by duloxetine.
Topics: Aged; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Thiophenes | 2009 |
Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study.
Topics: Aged; Anxiety; Chronic Disease; Comorbidity; Depressive Disorder, Major; Disability Evaluation; Disease Management; Duloxetine Hydrochloride; Female; Health Status; Humans; Low Back Pain; Male; Pain Measurement; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Self Efficacy; Sleep; Surveys and Questionnaires; Thiophenes | 2010 |
Relationship between TSH levels in the normal range and short-term duloxetine efficacy.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Personality Inventory; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Thyrotropin; Treatment Outcome | 2010 |
Duloxetine related effects of brain structure on a patient of major depressive disorder with panic disorder.
Topics: Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Panic Disorder; Thiophenes | 2010 |
Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Topics: Adult; Antidepressive Agents; Citalopram; Cognition Disorders; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Reference Values; Selective Serotonin Reuptake Inhibitors; Thiophenes; Wechsler Scales | 2010 |
Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Personality Inventory; Prognosis; Psychometrics; Randomized Controlled Trials as Topic; Retrospective Studies; Thiophenes; Treatment Outcome | 2010 |
A case study of salami slicing: pooled analyses of duloxetine for depression.
Topics: Advertising; Antidepressive Agents; Clinical Trials as Topic; Conflict of Interest; Depressive Disorder, Major; Drug Industry; Duloxetine Hydrochloride; Humans; Meta-Analysis as Topic; Publishing; Thiophenes; Treatment Outcome | 2010 |
Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Magnetic Resonance Imaging; Male; Panic Disorder; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2010 |
Management of depression in the presence of pain symptoms.
Topics: Antidepressive Agents; Brain; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Fibromyalgia; Humans; Milnacipran; Mind-Body Relations, Metaphysical; Norepinephrine; Pain; Psychotherapy; Serotonin; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Attention Deficit Disorder with Hyperactivity; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Executive Function; Female; Humans; Male; Neuropsychological Tests; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2010 |
A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Topics: Antidepressive Agents; Brain; Cerebellum; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Panic Disorder; Psychiatric Status Rating Scales; Temporal Lobe; Thiophenes; Time Factors; Treatment Outcome | 2011 |
Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder.
Topics: Adult; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pain; Pain Measurement; Thiophenes; Treatment Outcome | 2010 |
Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Markov Chains; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recurrence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sweden; Thiophenes; Venlafaxine Hydrochloride | 2010 |
Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Prescriptions; Duloxetine Hydrochloride; Female; Humans; Male; Managed Care Programs; Medical Records; Medication Adherence; Middle Aged; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Young Adult | 2010 |
Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials.
Topics: Adult; Antidepressive Agents; Compassionate Use Trials; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Duloxetine Hydrochloride; Female; Humans; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Thiophenes; Time | 2010 |
[The weeping patient].
Topics: Antidepressive Agents; Crying; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Physician-Patient Relations; Primary Health Care; Thiophenes | 2010 |
Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Socioeconomic Factors; Thiophenes; United States; United States Department of Veterans Affairs; Veterans Health; Young Adult | 2010 |
Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Duloxetine Hydrochloride; Humans; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2010 |
A case of venlafaxine-induced bruxism alleviated by duloxetine substitution.
Topics: Aged; Antidepressive Agents; Bruxism; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Synergism; Duloxetine Hydrochloride; Female; Humans; Hypertension; Middle Aged; Piperazines; Quinolones; Thiophenes | 2011 |
[Effective treatment of depression. Early reduction of painful concomitant symptoms increases the probability of remission].
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Early Diagnosis; General Practice; Humans; Pain; Quality of Life; Somatoform Disorders; Thiophenes | 2010 |
[Interview with Dr. Armin Spingler. Management of depression in family practice].
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; General Practice; Humans; Medication Adherence; Pain; Somatoform Disorders; Thiophenes | 2010 |
False conclusions regarding duloxetine's purported efficacy in pain among depressed patients.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Pain; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2010 |
On the three-arm non-inferiority trial including a placebo with a prespecified margin.
Topics: Algorithms; Antidepressive Agents; Computer Simulation; Confidence Intervals; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Models, Statistical; Monte Carlo Method; Multicenter Studies as Topic; Normal Distribution; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Sample Size; Thiophenes; Treatment Outcome | 2011 |
Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Databases, Factual; Depressive Disorder, Major; Duloxetine Hydrochloride; Hospitalization; Humans; Medication Adherence; Middle Aged; Thiophenes; Time Factors; Young Adult | 2011 |
Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Costs; Duloxetine Hydrochloride; Female; Health Care Costs; Humans; Male; Middle Aged; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Measurement-based care in psychiatric practice: a policy framework for implementation.
Topics: Adult; Antidepressive Agents; Cooperative Behavior; Depressive Disorder, Major; Disease Management; Duloxetine Hydrochloride; Female; Health Plan Implementation; Humans; Interdisciplinary Communication; Medication Adherence; Outcome and Process Assessment, Health Care; Standard of Care; Surveys and Questionnaires; Thiophenes | 2011 |
Hypogonadism and gynecomastia with duloxetine.
Topics: Bulimia Nervosa; Depressive Disorder, Major; Duloxetine Hydrochloride; Gynecomastia; Humans; Hypogonadism; Male; Mastectomy; Selective Serotonin Reuptake Inhibitors; Thiophenes; Young Adult | 2011 |
Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine.
Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Stevens-Johnson Syndrome; Thiophenes | 2011 |
Duloxetine transfer across the placenta during pregnancy and into milk during lactation.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Lactation; Milk, Human; Placenta; Pregnancy; Thiophenes | 2011 |
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Topics: Adolescent; Adult; Algorithms; Antidepressive Agents; Chronic Disease; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dosage Forms; Duloxetine Hydrochloride; Female; Humans; Male; Medication Adherence; Middle Aged; Pain; Retrospective Studies; Somatoform Disorders; Thiophenes; Venlafaxine Hydrochloride; Young Adult | 2011 |
Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cytokines; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Hypericum; Impulsive Behavior; Inflammation; Kynurenine; Male; Middle Aged; Neopterin; Phytotherapy; Recurrence; Serotonin; Smoking; Suicide, Attempted; Thiophenes; Tryptophan; Young Adult | 2011 |
Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series.
Topics: Adult; Antidepressive Agents; Brain Stem; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Male; Organ Size; Panic Disorder; Putamen; Thiophenes | 2011 |
Duloxetine-induced subcortical growth in a patient with major depressive disorder and panic disorder.
Topics: Adult; Antidepressive Agents; Brain Stem; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Organ Size; Panic Disorder; Putamen; Thiophenes | 2011 |
Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.
Topics: Adult; Antidepressive Agents; Catechol O-Methyltransferase; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Sex Factors; Thiophenes | 2011 |
Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background?
Topics: Adult; Antidepressive Agents; Case-Control Studies; Depression; Depressive Disorder; Depressive Disorder, Major; Dopamine; Duloxetine Hydrochloride; Electroretinography; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Sample Size; Thiophenes; Treatment Outcome | 2011 |
Safety of electroconvulsive therapy-duloxetine combination.
Topics: Antidepressive Agents; Antipsychotic Agents; Combined Modality Therapy; Depressive Disorder, Major; Dibenzothiazepines; Duloxetine Hydrochloride; Electroconvulsive Therapy; Female; Humans; Male; Middle Aged; Quetiapine Fumarate; Suicidal Ideation; Thiophenes; Treatment Outcome | 2011 |
Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Logistic Models; Male; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Severity of Illness Index; Thiophenes; Treatment Outcome | 2011 |
Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Follow-Up Studies; Health Care Costs; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Regression Analysis; Retrospective Studies; Thiophenes; United States; Young Adult | 2011 |
Duloxetine's effects in resting functional magnetic resonance imaging of first-episode, drug-naive major depressive disorder with panic disorder patients.
Topics: Adolescent; Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Male; Panic Disorder; Rest; Thiophenes | 2011 |
Comparative effectiveness in pain-related outcomes and health care utilizations between veterans with major depressive disorder treated with duloxetine and other antidepressants: a retrospective propensity score-matched comparison.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents; Chronic Pain; Cohort Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain Measurement; Retrospective Studies; Thiophenes; Veterans; Young Adult | 2012 |
Partial status epilepticus after electroconvulsive therapy and medical treatment with bupropion.
Topics: Adrenergic Uptake Inhibitors; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Duloxetine Hydrochloride; Electroconvulsive Therapy; Electroencephalography; Humans; Male; Seizures; Status Epilepticus; Thiophenes | 2011 |
Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Insurance, Health, Reimbursement; Logistic Models; Male; Middle Aged; Thiophenes; United States; Withholding Treatment; Young Adult | 2012 |
Duloxetine in the acute and continuation treatment of major depressive disorder.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Thiophenes | 2011 |
Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multivariate Analysis; Thiophenes; United States | 2011 |
Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Thiophenes | 2011 |
Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Thiophenes | 2011 |
Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Multicenter Studies as Topic; Pain; Pain Measurement; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Frontal regional homogeneity increased and temporal regional homogeneity decreased after remission of first-episode drug-naïve major depressive disorder with panic disorder patients under duloxetine therapy for 6 weeks.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Panic Disorder; Remission Induction; Temporal Lobe; Thiophenes | 2012 |
Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Biomarkers, Pharmacological; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Genetic Association Studies; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Corticotropin-Releasing Hormone; Thiophenes | 2013 |
Agomelatine-induced akathisia with concomitant duloxetine medication: a case report.
Topics: Acetamides; Adult; Akathisia, Drug-Induced; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Thiophenes | 2012 |
Generalized tonic-clonic seizure secondary to duloxetine poisoning: a short report with favorable out come.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Electroencephalography; Humans; Male; Status Epilepticus; Thiophenes | 2012 |
Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom.
Topics: Adult; Aged; Analgesics; Antidepressive Agents; Databases, Factual; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Health Services Needs and Demand; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Thiophenes; United Kingdom | 2012 |
Fast versus slow onset of depressive episodes: a clinical criterion for subtyping patients with major depression.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Life Change Events; Male; Middle Aged; Suicide, Attempted; Thiophenes; Time Factors | 2013 |
Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?
Topics: Adult; Aged; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Tolerance; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Precision Medicine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes | 2012 |
A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Likelihood Functions; Multiple Sclerosis, Relapsing-Remitting; Placebos; Poisson Distribution; Randomized Controlled Trials as Topic; Research Design; Sample Size; Therapeutic Equivalency; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Serotonin-norepinephrine reuptake inhibitor treatment for tinnitus and depression.
Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder, Major; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Male; Selective Serotonin Reuptake Inhibitors; Thiophenes; Tinnitus; Treatment Outcome | 2012 |
Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
Topics: Adult; Antidepressive Agents; Biomarkers; Case-Control Studies; Cytokines; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-1beta; Interleukin-2; Interleukin-4; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Increases in amplitude of low-frequency fluctuations in left fronto-parietal area after duloxetine therapy in first-episode, drug-naïve, major depressive disorder with panic disorder patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Frontal Lobe; Functional Laterality; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Oxygen; Panic Disorder; Parietal Lobe; Thiophenes; Young Adult | 2012 |
A case of severe hyponatremia induced by duloxetine and ziprasidone.
Topics: Antidepressive Agents; Antipsychotic Agents; Creatine Kinase; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Hyponatremia; Middle Aged; Piperazines; Thiazoles; Thiophenes | 2012 |
Antidepressant use in underweight older adults.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Appetite; Body Mass Index; Body Weight; Depressive Disorder, Major; Duloxetine Hydrochloride; Hospitals, University; Humans; Inservice Training; Mianserin; Mirtazapine; Practice Patterns, Physicians'; Retrospective Studies; Thinness; Thiophenes | 2012 |
Interactive medical case. A patient found unresponsive.
Topics: Adolescent; Anorexia Nervosa; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Diagnosis, Differential; Dibenzothiazepines; Duloxetine Hydrochloride; Electrocardiography; Female; Humans; Hypokalemia; Quetiapine Fumarate; Suicide, Attempted; Thiophenes; Unconsciousness | 2012 |
Association of candidate gene polymorphisms with diastolic blood pressure change in patients treated with duloxetine.
Topics: Adrenergic Uptake Inhibitors; Blood Pressure; Catechol O-Methyltransferase; Depressive Disorder, Major; Diastole; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Pain; Polymorphism, Single Nucleotide; Receptors, Adrenergic, beta-2; Receptors, Dopamine; Receptors, Serotonin; Thiophenes | 2013 |
Antidepressant-selective gynecomastia.
Topics: Aged; Amlodipine; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluorobenzenes; Gynecomastia; Humans; Male; Pyrimidines; Rosuvastatin Calcium; Sertraline; Sulfonamides; Thiophenes | 2013 |
Duloxetine for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Thiophenes; Treatment Outcome | 2002 |
A word of caution about the implied role for duloxetine in pain management.
Topics: Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Pain; Pain Measurement; Somatoform Disorders; Thiophenes; Treatment Outcome | 2003 |
[Physical recovery is part of remission].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Nursing Assessment; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Thiophenes; Treatment Outcome | 2004 |
The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
Topics: Analysis of Variance; Antidepressive Agents; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Depressive Disorder, Major; Drug Approval; Duloxetine Hydrochloride; Endpoint Determination; Humans; Longitudinal Studies; Models, Statistical; Pain Measurement; Placebos; Psychiatric Status Rating Scales; Thiophenes; Treatment Outcome | 2004 |
Duloxetine hydrochloride.
Topics: Animals; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Marketing; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2004 |
[Duloxetine receives positive recommendation by the Scientific Committee of EMEA for treatment of depression].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Diabetic Neuropathies; Drug Approval; Duloxetine Hydrochloride; Europe; Humans; Pharmacy and Therapeutics Committee; Selective Serotonin Reuptake Inhibitors; Thiophenes; Urinary Incontinence, Stress | 2004 |
Duloxetine for the treatment of major depressive disorder in older patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Pain; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2005 |
Duloxetine fights major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Thiophenes | 2005 |
Duloexetine (Cymbalta) for treatment of major depressive disorder.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2005 |
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
[Brief case report. Duloxetine in Cotard syndrome].
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Delusions; Depersonalization; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Long-Term Care; Olanzapine; Risperidone; Syndrome; Thiophenes | 2005 |
The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome | 2006 |
Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2006 |
Duloxetine treatment of major depressive episodes in the course of psychotic disorders.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Personality Inventory; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiophenes; Treatment Outcome | 2006 |
Duloxetine for childhood depression with pain and dissociative symptoms.
Topics: Antidepressive Agents; Benzodiazepines; Child; Depressive Disorder, Major; Dissociative Disorders; Duloxetine Hydrochloride; Female; Humans; Olanzapine; Pain; Thiophenes | 2006 |
Combined use of ECT with duloxetine and olanzapine: a case report.
Topics: Adult; Benzodiazepines; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Electroconvulsive Therapy; Female; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Thiophenes | 2006 |
Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.
Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Thiophenes | 2006 |
Duloxetine and hyponatremia: a report of 5 cases.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Hyponatremia; Male; Middle Aged; Thiophenes | 2007 |
A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anxiety Disorders; Depressive Disorder, Major; Diabetic Neuropathies; Duloxetine Hydrochloride; Female; Fibromyalgia; Humans; Male; Middle Aged; Prevalence; Retrospective Studies; Thiophenes; United States; Urinary Incontinence, Stress | 2007 |
Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.
Topics: Abdominal Pain; Adolescent; Antidepressive Agents; Chronic Disease; Comorbidity; Crohn Disease; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Low Back Pain; Pain; Sick Role; Thiophenes | 2007 |
Simple options for improving signal detection in antidepressant clinical trials.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Fluoxetine; Likelihood Functions; Models, Statistical; Paroxetine; Personality Inventory; Placebo Effect; Psychometrics; Reproducibility of Results; Research Design; Signal Detection, Psychological; Thiophenes; Treatment Outcome | 2007 |
Manic switching in patients receiving duloxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Bipolar Disorder; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychotic Disorders; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes | 2007 |
Duloxetine--three birds with one stone?
Topics: Antidepressive Agents; Depressive Disorder, Major; Diabetic Neuropathies; Duloxetine Hydrochloride; Humans; Selective Serotonin Reuptake Inhibitors; Thiophenes; Urinary Incontinence, Stress | 2007 |
Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Topics: Adrenergic Uptake Inhibitors; Adult; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Neurotransmitter Uptake Inhibitors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Thiophenes; Venlafaxine Hydrochloride | 2008 |
Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Neurotransmitter Uptake Inhibitors; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2008 |
Suicidal ideation associated with duloxetine use: a case series.
Topics: Adult; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Risk Factors; Selective Serotonin Reuptake Inhibitors; Suicide; Thinking; Thiophenes | 2008 |
Successful treatment of nicotine withdrawal with duloxetine: a case report.
Topics: Adult; Alcohol Drinking; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Smoking; Substance Withdrawal Syndrome; Thiophenes; Tobacco Use Disorder | 2008 |
Duloxetine-induced cutaneous adverse reaction.
Topics: Adrenergic Uptake Inhibitors; Depressive Disorder, Major; Duloxetine Hydrochloride; Exanthema; Female; Humans; Middle Aged; Pruritus; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2008 |
Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Histamine H1 Antagonists; Humans; Male; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Thiophenes; Treatment Outcome | 2008 |
Response to duloxetine in a depressed, treatment-resistant adolescent female.
Topics: Adolescent; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Phototherapy; Seasons; Thiophenes; Treatment Outcome | 2007 |
A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Duloxetine Hydrochloride; Humans; Markov Chains; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Thiophenes; Treatment Outcome; United States | 2008 |